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ercutaneous Coronary
ntervention, Diabetes
ellitus, and Death*
arold L. Dauerman, MD
urlington, Vermont
n this issue of the Journal, Banning et al. (1) present the
mportant diabetes mellitus subgroup analysis of the SYNTAX
SYNergy between percutaneous coronary intervention with
AXus and cardiac surgery) trial. The SYNTAX trial
ompared 1,800 patients with symptomatic left main and/or
-vessel coronary artery disease (CAD) treated with drug-
luting stents (DES) versus coronary artery bypass graft
urgery (CABG) (2). The overall results of the trial dem-
nstrate 1-year inferiority of percutaneous coronary inter-
ention (PCI) compared with CABG with respect to major
dverse cardiac and cerebrovascular events (MACCE)—
See page 1067
eath, myocardial infarction (MI), stroke, or repeat revas-
ularization (17.8% vs. 12.4%, p  0.004). But the individ-
al component end points are clinically relevant: mortality
nd MI rates were similar with either approach, stroke was
.7-fold higher with CABG, and repeat revascularization
as 2.3-fold higher with PCI. The pre-specified subgroup
nalysis of the 452 patients with diabetes demonstrates
imilar results as the overall trial: mortality and MI rates are
imilar at 1 year; stroke rates, though, are no longer
tatistically higher in the CABG group, but repeat revascu-
arization remains threefold higher with PCI as compared
ith CABG. On the basis of the SYNTAX trial findings,
ave DES removed the “death penalty” associated with
iabetes and multivessel PCI (3,4)?
iabetes and Death: An Accidental Finding
he BARI (Bypass Angioplasty Revascularization Investi-
ation) trial was initiated by the National Heart, Lung, and
lood Institute in 1987 and firmly established diabetes as an
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of Vermont College of Medicine, Burlington, Vermont.C
r. Dauerman is a consultant to and/or has research grants from Abbott Vascular,
edtronic, The Medicines Company, St. Jude Medical, and Bristol-Myers Squibb.mportant clinical risk factor among patients referred to
ardiac catheterization laboratories (3,5). The BARI trial
andomized approximately the same number of patients as
YNTAX to PCI versus CABG; the similarities between
ARI and SYNTAX stop there (Table 1). The BARI study
as a trial of balloon angioplasty, the SYNTAX study was
trial of DES. The SYNTAX study looked for left main
isease, the BARI study excluded it. The BARI trial did not
nclude periprocedural MI or 1 -year repeat revasculariza-
ion in their primary or secondary end points, whereas
YNTAX used a broad and complex primary end point of
ACCE. Given the contrasting nature of these trials, why
ook back and compare?
We look back to BARI and forward to BARI 2D (Bypass
ngioplasty Revascularization Investigation in Type 2 Di-
betes) as these trials sandwich SYNTAX in a context that
ight simply be summarized as “PCI is bad for patients
ith diabetes and multivessel CAD.” This is a major issue
or clinicians: current registries estimate that approximately
ne-third of patients undergoing PCI have diabetes (6).
here is a rationale for this definitive interpretation: the
ARI diabetic subgroup showed a 15% lesser survival with
CI as compared with CABG at 5-year follow-up (3). And
he BARI 2D trial failed to show a benefit of PCI as
ompared with intensive medical therapy among 1,605
table, elective diabetic patients in the PCI stratum (7).
urthermore, the SYNTAX trial is a “negative trial” that
ailed to show noninferiority of MACCE for PCI as
ompared with CABG (2). Thus, all SYNTAX subgroup
nalyses may come with a disclaimer that negates their
linical impact.
The SYNTAX diabetes subgroup (n 452) is 25% larger
han the BARI diabetes subgroup (n  365), and thus
rovides a significant amount of new and potentially im-
ortant data. Before we assume that this pre-specified
ubgroup analysis is unable to influence clinical behavior, it
s worthwhile to recall how the BARI trial influenced the
ulture of diabetes and revascularization: it was an accident
ediated by an astute Data Safety and Monitoring Board
fter completion of trial enrollment from 1988 to 1991. As
er the Methods section of the original BARI manuscript,
In 1992, the Safety and Data Monitoring Board requested
n analysis of diabetic patients on the basis of published
eports of adverse outcomes of PTCA after thrombolytic
herapy in a subgroup of patients” (5,8). The startling
elationship between diabetes, balloon angioplasty, and
eath discovered from this non–pre-specified subgroup
nalysis was not confirmed in the BARI registry, where
linicians were able to choose lower risk diabetic patients for
CI without conferring the death penalty (9). Nevertheless,
he BARI trial subgroup analysis had a significant impact:
he National Heart, Lung, and Blood Institute utilized this
ubgroup analysis to issue a Clinical Alert recommending
ABG over angioplasty for diabetic patients (10).
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March 16, 2010:1076–9 Revascularization and DiabetesGiven that the diabetes mandate arose from a not
re-specified subgroup analysis, the BARI study authors
ppropriately caution the clinical implications of this finding
ith “appropriate concern about the potential of a spurious
nding” (11). Despite the reliance on an ad hoc subgroup
nalysis, the Clinical Alert seems in hindsight to be appro-
riate, and balloon angioplasty for multivessel disease in
iabetic patients seems like a very bad idea indeed. The 7-
nd 10-year follow-up of the BARI trial diabetic patient
hows a persistent and growing benefit for survival with
ABG as opposed to balloon angioplasty for patients with
iabetes (11,12). More recently, a meta-analysis of 10
andomized trials of PCI (balloon angioplasty or bare
etal stents) versus CABG for patients with multivessel
AD again suggests an interaction between death and
evascularization strategy only for patients with treated
iabetes (4). Thus, the diabetes subgroup analysis in the
ARI trial was like the proverbial apple falling on
ewton’s head: it identified an entirely new way to look
t an important issue—in this case, risk stratification for
evascularization approaches based upon clinical (and not
natomic) criteria.
iabetes and PCI: SYNTAX in Context
s with the BARI study, we should not ignore the clinical
mplications of the important subgroup analysis of diabetic
atients despite the overall negative results of the SYNTAX
elected Randomized Clinical Trials of Revascularization and DiabeTable 1 Selected Randomized Clinical Trials of Revascularizatio
Diabe
BARI
N 353
Randomization PTCA vs. CABG DE
Follow-up reported 10 yrs 1
PCI method Balloon angioplasty Ta
Patients Symptomatic multivessel CAD Sy
Primary end point Death 5 yrs De
Death PTCA: 34.5% DE
CABG: 19.4% CA
p  0.002 p 
Death
MI Not reported At
Stroke DE
CA
p 
Death Not reported DE
MI CA
Stroke p 
Revascularization
Repeat revascularization PTCA: 69.9% DE
CABG: 11.1% (at 7 yrs) CA
p 
Interaction with anatomic complexity No Ye
ARI  Bypass Angioplasty Revascularization Investigation; CABG  coronary artery bypass graft
yocardial infarction; PTCA  percutaneous transluminal coronary angiography; SYNTAX  SYNerial. The SYNTAX investigators have discovered the fol- Powing with respect to diabetes and revascularization: 1) at
year, there is no death penalty associated with multivessel
CI; 2) there are no differences in death/MI/stroke between
ABG and PCI at 1 year; and 3) the use of DES fails to
urn diabetic patients into nondiabetic patients—namely,
he risk of repeat revascularization at 1 year remains sub-
tantially higher for diabetic patients as compared with
ondiabetic patients, and threefold higher than for patients
ndergoing CABG. These findings are consistent with
athophysiologic differences between the responses to stent
mplantation of patients with and without diabetes (13).
The results of the SYNTAX subgroup analysis should
lso be seen in context: the 3-year results of the ARTS II
Arterial Revascularization Therapies Study-Part II) regis-
ry are concordant with SYNTAX and suggest similar
ong-term safety and mortality of DES-based PCI as
ompared with CABG for diabetic patients. Also similarly,
epeat revascularization rates was higher with PCI for
iabetic patients as compared with nondiabetic patients
espite the use of DES (14).
What should a clinician do tomorrow when faced with a
iabetic patient and multivessel CAD in the catheterization
aboratory? The BARI 2D study helps us understand what
s the current standard of care. The BARI 2D trial randomly
llocated patients to intensive medical therapy versus revas-
ularization, but replicated the BARI Registry with respect
o revascularization: investigators could choose between
ellitusd Diabetes Mellitus
ients All Diabetic Patients
SYNTAX BARI 2D
452 2,368
ABG All revascularization vs. Med Rx
5 yrs
S 35% DES
atic left main and/or multivessel CAD Elective, left main excluded
I, stroke, or revascularization 1 yr Death 5 yrs
% All revascularization: 11.7%
4% Med Rx: 12.2%
p  0.97
At 5 yrs:
1% All revascularization: 22.8%
.3% Med Rx: 24.1%
p  0.70
0% Not reported
.2%
3
3% 42% of Med Rx patients crossover to
revascularization group4%
1
Not reported
; CAD  coronary artery disease; DES  drug-eluting stent(s); Med Rx medical treatment; MI 
ween percutaneous coronary intervention with TAXus and cardiac surgery.tes Mn an
tic Pat
S vs. C
yr
xus DE
mptom
ath, M
S: 8.4
BG: 6.
0.43
1 yr:
S: 10.
BG: 10
0.96
S: 26.
BG: 14
0.00
S: 20.
BG: 6.
0.00
sCI or CABG for patients with diabetes. Surprisingly, the
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Revascularization and Diabetes March 16, 2010:1076–9ajority of diabetic patients with multivessel CAD in the
ARI 2D trial (56%) underwent PCI, not CABG (15).
urthermore, consistent with findings from the CRUSADE
Can Rapid Risk Stratification of Unstable Angina Patients
uppress Adverse Outcomes With Early Implementation of
he American College of Cardiology/American Heart As-
ociation Guidelines) registry, the preference for PCI grew
fter the approval of DES (16). Importantly, investigators in
oth the BARI 2D trial and the BARI Registry made
evascularization choices on the basis of severity and extent
f disease (i.e., proximal left anterior descending artery
esions, chronic total occlusions, triple-vessel disease)
15,17). Furthermore, patients did not necessarily present
quivalent revascularization options: among patients as-
igned to PCI in the BARI 2D study, only 49% were
eemed equally suitable for CABG; and among patients
elected for CABG, only 11% were deemed suitable for
CI (15).
Thus, clinicians are already performing multivessel PCI
n diabetic patients, many of whom investigators believe
ould not be served at all with CABG because of a variety
f comorbidities (risk of stroke) or anatomic challenges
diffuse distal vessel disease, poor conduits). The SYNTAX
tudy diabetes analysis does not tell those clinicians to stop
oing PCI in diabetic patients. The SYNTAX study instead
resents PCI as a viable general option with the following
aveats: 1) multivessel PCI for diabetic patients performed
ithout DES is likely associated with increased death and
hould not be done unless there is no reasonable surgical
ption (3,4); 2) diabetic patients undergoing PCI with DES
emain at higher risk for repeat revascularization with PCI
ersus CABG. The influence of both culprit and nonculprit
esion progression in all diabetic patients should be consid-
red (18,19); and 3) we cannot wait for the 5-year follow-up
f the SYNTAX diabetes study to act clinically. It is
ossible that a death penalty is not seen at 1 year but will
ppear at longer follow-up periods. Ongoing studies, such
s the FREEDOM (Future Revascularization Evaluation in
atients With Diabetes Mellitus: Optimal Management of
ultivessel Disease) trial (20), can be expected to help
urther shape our choice of treatment strategies.
Finally, the SYNTAX study was a trial of complex,
igh-risk PCI performed by skilled investigators at high-
olume institutions: can the findings be replicated in com-
unity practice? Although the SYNTAX trial no longer
onfirms the mortality risk associated with PCI for diabetic
atients, the BARI study’s accidental finding taught us an
mportant lesson: PCI for patients with multivessel CAD
nd diabetes, like left main or bifurcation PCI, remains a
igher risk procedure. We have no reason to believe that
ommunity clinicians cannot translate the results of the
YNTAX trial into a practice pattern that judiciously
hooses diabetic patients for either CABG or DES-based
CI: both the old (BARI) and the new (EVENT [Evalu-
tion of Drug-Eluting Stents and Ischemic Events]) regis-
ries have demonstrated that multivessel PCI for diabetes iseasible and safe outside the confines of a randomized
linical trial (6,9). Thus, reversal of the BARI trial mortality
ignal moves the diabetic revascularization choice away from
he black-or-white, life-or-death decision the BARI trial
nce described; instead, we can move diabetes, CABG, and
CI back into the typical gray areas of clinical decision
aking that characterize routine practice.
eprint requests and correspondence: Dr. Harold L. Dauerman,
ardiac Unit, McClure 1, Fletcher Allen Health Care, University
f Vermont, 111 Colchester Avenue, Burlington, Vermont 05401.
-mail: harold.dauerman@vtmednet.org.
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